ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

FTH vs EOLS // GROSS PROFIT MARGIN

Faeth Therapeutics Inc. (NASDAQ) VS. Evolus Inc. (NASDAQ) • 15-METRIC TALLY: FTH 1 — EOLS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FTH VS. EOLS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC FTH EOLS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 66.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -4.22% -9.20% +4.98 FTH /fcf-yield <GO>
Operating Margin — -11.00% — TIE /operating-margins <GO>
Net Profit Margin — -17.40% — TIE /net-margins <GO>
Revenue Growth (YoY) — 11.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 EOLS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.9 46.4 -11.50 EOLS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $483.0M $485.5M -$2.5M EOLS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR FTH REV EOLS REV FTH GROSS % EOLS GROSS % FTH FCF EOLS FCF
FY 2025 $62.4M $297.2M — 66.3% -$20.5M -$45.7M
FY 2024 $91.3M $266.3M — 68.5% -$24.8M -$19.5M
FY 2023 $103.8M $202.1M — — -$32.0M -$34.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FTH // BETA —
EOLS // BETA —